SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,126 | +73.0% | 422,008 | +149.4% | 0.00% | +100.0% |
| Q2 2023 | $3,541 | -82.9% | 169,195 | -82.8% | 0.00% | -80.0% |
| Q1 2023 | $20,737 | -15.4% | 981,886 | +1.9% | 0.01% | -9.1% |
| Q4 2022 | $24,517 | -99.6% | 963,336 | +249.3% | 0.01% | +57.1% |
| Q3 2022 | $6,626,000 | +7429.5% | 275,759 | +5906.5% | 0.01% | – |
| Q2 2022 | $88,000 | -93.2% | 4,591 | -93.8% | 0.00% | -100.0% |
| Q1 2022 | $1,290,000 | -96.2% | 74,234 | -95.2% | 0.00% | -83.3% |
| Q4 2021 | $33,952,000 | +341.6% | 1,550,952 | +285.4% | 0.01% | +100.0% |
| Q3 2021 | $7,689,000 | +681.4% | 402,388 | +601.8% | 0.00% | – |
| Q2 2021 | $984,000 | -39.0% | 57,338 | -20.5% | 0.00% | -100.0% |
| Q1 2021 | $1,613,000 | +613.7% | 72,159 | +608.6% | 0.00% | – |
| Q4 2020 | $226,000 | +15.3% | 10,183 | -23.1% | 0.00% | – |
| Q3 2020 | $196,000 | -73.4% | 13,244 | -73.3% | 0.00% | -100.0% |
| Q2 2020 | $736,000 | +643.4% | 49,648 | +455.3% | 0.00% | – |
| Q1 2020 | $99,000 | -54.6% | 8,941 | -64.2% | 0.00% | – |
| Q4 2019 | $218,000 | +96.4% | 24,941 | +66.9% | 0.00% | – |
| Q3 2019 | $111,000 | -33.5% | 14,944 | -16.2% | 0.00% | – |
| Q2 2019 | $167,000 | +247.9% | 17,825 | +93.3% | 0.00% | – |
| Q1 2019 | $48,000 | -7.7% | 9,222 | -22.2% | 0.00% | – |
| Q4 2018 | $52,000 | -63.9% | 11,852 | -33.9% | 0.00% | – |
| Q3 2018 | $144,000 | +100.0% | 17,933 | +75.9% | 0.00% | – |
| Q2 2018 | $72,000 | -32.1% | 10,194 | +36.6% | 0.00% | – |
| Q1 2018 | $106,000 | +82.8% | 7,462 | +11.8% | 0.00% | – |
| Q4 2017 | $58,000 | -65.5% | 6,677 | -53.6% | 0.00% | – |
| Q3 2017 | $168,000 | +140.0% | 14,404 | +185.6% | 0.00% | – |
| Q2 2017 | $70,000 | -15.7% | 5,044 | -17.5% | 0.00% | – |
| Q1 2017 | $83,000 | +102.4% | 6,111 | +5.2% | 0.00% | – |
| Q4 2016 | $41,000 | -51.8% | 5,807 | +3.0% | 0.00% | – |
| Q3 2016 | $85,000 | +962.5% | 5,637 | +606.4% | 0.00% | – |
| Q2 2016 | $8,000 | – | 798 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |